SC Asks Uttarakhand Govt To Finalize Decision On Suspension Of 14 Patanjali Products In Two Weeks

New Delhi: The Supreme Court on Tuesday directed the Uttarakhand government to decide on the suspension of 14 products by yoga guru Ramdev’s Patanjali Ayurved, reported Live Law.

A bench of Justices Hima Kohli and Sandeep Mehta directed the Bharatiya Janata Party government in the state to decide on the matter within two weeks.

On April 29, the Uttarakhand State Licensing Authority for Ayurvedic and Unani Services told the court that the licences were suspended as Patanjali Ayurved had repeatedly violated the 1945 Drugs and Cosmetic Rules.

The 14 drugs that had been suspended were: Swasari Gold, Swasari Vati, Bronchom, Swasari Pravahi, Swasari Avaleh, Mukta Vati Extra Power, Lipidom, Bp Grit, Madhugrit, Madhunashini Vati Extra Power, Livamrit Advance, Livogrit, Eyegrit Gold and Patanjali Drishti Eye Drop.

At the previous hearing on July 9, Patanjali Ayurved told a bench of Justices Hima Kohli and Sandeep Mehta that it had instructed 5,606 franchise stores to withdraw these products.

Media platforms were also instructed to withdraw advertisements for the 14 products, said the company. The court had asked Patanjali Ayurved to file an affidavit within two weeks, stating if social media intermediaries had withdrawn advertisements for the products.

At Tuesday’s hearing, the Indian Medical Association told the court that the 14 products were still available over the counter, even though Patanjali had earlier reportedly stopped their manufacturing.

Patanjali then told the court that the state government cancelled the suspension order on July 1 after considering the report of a committee constituted to look into the matter, reported Live Law.

Related Posts

Puresta launches EVERQ, AI-powered skin-health platform

Puresta Lifestyle Private Limited announced the launch of EVERQ, an AI-powered skin-health platform designed to bring skin assessment, dermatologist consultations, personalised treatment and ongoing skincare together in one connected journey.…

Stem cell therapy for autism only in approved clinical trials: Centre

Stem cell interventions that have not been approved for routine clinical use, including those offered for autism, should not be provided as routine, standard or commercial clinical services, the advisory…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Puresta launches EVERQ, AI-powered skin-health platform

Puresta launches EVERQ, AI-powered skin-health platform

Stem cell therapy for autism only in approved clinical trials: Centre

Stem cell therapy for autism only in approved clinical trials: Centre

US FDA launches expedited IND Pilot, begins accepting applications

US FDA launches expedited IND Pilot, begins accepting applications

PIL in SC seeks time-bound probe, stringent action against fake drug networks

PIL in SC seeks time-bound probe, stringent action against fake drug networks

Ghaziabad: Fake supplement racket busted, 5 held

Ghaziabad: Fake supplement racket busted, 5 held

22 medical stores raided in Hisar, 7 stocked dual-use drugs without records

22 medical stores raided in Hisar, 7 stocked dual-use drugs without records